Project Grant K08HL173564
Award Date
9/15/24
Completion Date
8/31/29
Dollars Obligated
$155K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 4-year, $721,826 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant funds research to identify molecular mechanisms regulating the function of alveolar matrix fibroblasts and their role in supporting vascular network formation during postnatal lung development. The research aims to elucidate the transcriptional regulator MEOX2 and...
This $203,974 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research project to investigate the effects of normal and diseased extracellular matrix (ECM) on the self-renewal and differentiation of airway basal epithelial cells. The project leverages novel tools developed by the co-PIs, including "inside-out" airway organoids and ECM hydrogels derived from normal and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $740,317 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Washington University in St. Louis to study the regulation of primary and secondary alveologenesis by FGF signaling pathways. The research aims to identify the cellular mechanisms by which FGF signaling regulates cell proliferation, differentiation, and death during the first and second stages of alveolar development. This work could provide insights into...
This $600,761 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the role of the NKG2D receptor and its ligands in driving lung inflammation and development of bronchopulmonary dysplasia (BPD) in preterm infants. The key objectives are to: 1) Investigate the contribution of NKG2D+ lung lymphocytes (gamma-delta T cells and NK cells) to LPS- and hyperoxia-induced lung...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to the Regents of the University of Michigan to conduct research on the mechanisms underlying lung injury, fibrosis, and susceptibility to bacterial infections. The key objectives are to study: 1) how epithelial cell signaling regulates fibrosis and interacts with myeloid cells, 2) the impaired innate immunity against...
This $651,019 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to elucidate the mechanisms behind dysfunctional epithelial repair processes that contribute to the development of pulmonary fibrosis. The research aims to identify factors driving aberrant epithelial cell states, determine the role of HIF signaling in preventing functional alveolar repair, and investigate niche-specific mechanisms regulating...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at Northwestern University to investigate the role of mitochondrial metabolism in alveolar epithelial cell differentiation and the development of lung fibrosis. The $616,000 award, effective September 1, 2024 through August 31, 2029, will support experiments using genetic mouse models to determine how mitochondrial...
This $940,320 Cooperative Agreement awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports a 5-year research project led by Vanderbilt University Medical Center to investigate the molecular mechanisms underlying chronic parenchymal lung diseases like pulmonary fibrosis and bronchopulmonary dysplasia. The project aims to develop a spatially-resolved molecular atlas of chronic lung diseases,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $277,610 to Duke University to determine the role of TP53 regulation in alveolar epithelial transitional cell state, and the contribution of alveolar epithelial transitional cell state to pulmonary fibrosis. The project aims to uncover the molecular mechanisms that regulate alveolar epithelial cell states and understand the impact...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $545,400 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Georgia Tech Research Corp to elucidate the role of focal adhesion kinase (FAK) mechanosensing in extracellular matrix remodeling, senescence, and apoptosis-resistance in pulmonary fibrosis. The project will utilize a 3D bioengineered microtissue model to study these mechanisms in normal and senescent fibroblasts, and evaluate the...